AbbVie Inc. (NYSE:ABBV) EVP Jeffrey Ryan Stewart sold 25,290 shares of the company’s stock in a transaction on Tuesday, December 29th. The shares were sold at an average price of $105.00, for a total transaction of $2,655,450.00. Following the transaction, the executive vice president now owns 76,259 shares of the company’s stock, valued at $8,007,195. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
Shares of NYSE ABBV opened at $107.15 on Friday. The firm’s 50-day simple moving average is $103.69 and its 200 day simple moving average is $95.29. The company has a market cap of $189.17 billion, a price-to-earnings ratio of 22.65, a price-to-earnings-growth ratio of 1.67 and a beta of 0.84. The company has a quick ratio of 0.81, a current ratio of 0.95 and a debt-to-equity ratio of 5.38. AbbVie Inc. has a 12-month low of $62.55 and a 12-month high of $109.15.
AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, October 30th. The company reported $2.83 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.75 by $0.08. The business had revenue of $12.88 billion for the quarter, compared to the consensus estimate of $12.71 billion. AbbVie had a net margin of 18.16% and a return on equity of 439.24%. The firm’s quarterly revenue was up 51.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.33 EPS. On average, equities analysts expect that AbbVie Inc. will post 10.48 earnings per share for the current year.
Institutional investors have recently added to or reduced their stakes in the business. CVA Family Office LLC acquired a new position in AbbVie during the 3rd quarter valued at about $26,000. Harding Loevner LP lifted its position in AbbVie by 118.4% during the 3rd quarter. Harding Loevner LP now owns 332 shares of the company’s stock valued at $29,000 after purchasing an additional 180 shares during the period. James Investment Research Inc. acquired a new position in AbbVie during the 3rd quarter valued at about $32,000. Roble Belko & Company Inc lifted its position in AbbVie by 70.8% during the 3rd quarter. Roble Belko & Company Inc now owns 415 shares of the company’s stock valued at $36,000 after purchasing an additional 172 shares during the period. Finally, Horrell Capital Management Inc. acquired a new position in AbbVie during the 3rd quarter valued at about $39,000. Institutional investors own 64.15% of the company’s stock.
Several equities analysts recently commented on the stock. Morgan Stanley upped their target price on shares of AbbVie from $108.00 to $120.00 and gave the company an “overweight” rating in a research note on Monday, November 30th. The Goldman Sachs Group cut shares of AbbVie from a “neutral” rating to a “sell” rating in a research note on Tuesday, October 20th. Mizuho upped their target price on shares of AbbVie from $111.00 to $117.00 in a research note on Tuesday, December 15th. Berenberg Bank began coverage on shares of AbbVie in a report on Tuesday, September 29th. They issued a “hold” rating and a $98.00 price target on the stock. Finally, ValuEngine raised shares of AbbVie from a “strong sell” rating to a “sell” rating in a report on Tuesday, December 1st. Three investment analysts have rated the stock with a sell rating, four have assigned a hold rating and sixteen have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $112.50.
AbbVie Company Profile
AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal BehÃ§et's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrÃ¶m's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.
Read More: Straddles
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.